Predicting Response to Radiotherapy in Cancer-Induced Bone Pain: Cytokines as a Potential Biomarker?
Predicting Response to Radiotherapy in Cancer-Induced Bone Pain: Cytokines as a Potential Biomarker?
复制标题
DOI：
10.1016/j.clon.2020.03.010
复制
发表时间：
2020-10-01
影响因子：
3.4
通讯作者：
Sande, T. A.
中科院分区：
文献类型：
--
作者：
MacLeod, K.;Laird, B. J. A.;Sande, T. A.
目的：放射治疗（XRT）对癌症引起的骨痛（CIBP）有不同程度的疗效。预测可能疗效的生物标志物可以将XRT分层为最有可能受益的人群。在临床实践中没有使用生物标志物，但已鉴定出潜在的候选细胞因子。本研究的目的是研究候选细胞因子和镇痛反应之间的关系后XRT.Materials和方法：进行了探索性分析的生物银行数据从患者谁收到了单分数（8戈伊）XRT CIBP。生物库数据是从英国多个中心前瞻性收集的，作为一项更大规模临床试验的一部分，该试验获得了机构审查委员会的批准，所有患者都提供了在未来研究中使用其数据的书面知情同意书。在基线（XRT前24小时内）和随访（XRT后4周）时收集表型数据、疼痛评估以及血浆样本。基线和随访样本进行了分析和16个预先确定的细胞因子的水平进行了比较，在患者分类为XRT的“响应者”或“无响应者”。胰岛素样生长因子结合蛋白9（NOV/CCN 3/IGFBP-9）和白细胞介素-1 β（IL-1 β）被确定为XRT反应的潜在预测因子。对XRT的反应与基线时NOV/CCN 3/IGFBP-9的中位水平的比率之间显示出显著的关系：随访（P = 0.024）。此外，对于高达64岁的患者，NOV/CCN 3/IGFBP-9的中位水平在应答者和非应答者之间显著不同（P = 0.047）。对于IL-1 β，中位水平是显着不同的反应者和非反应者之间的乳腺癌患者（P = 0.006）。结论：虽然目前的研究结果没有确定强大的生物标志物，这是第一个这样的研究，以检查细胞因子在预测响应XRT的CIBP患者的作用，并鼓励研究，建立在这些研究结果。(C)2020年皇家放射科医师学院。由爱思唯尔有限公司出版。保留所有权利。
Aims: Radiotherapy (XRT) for cancer-induced bone pain (CIBP) has varying levels of efficacy. A biomarker that predicts likely efficacy could stratify XRT to those most likely to benefit. No biomarker is used in clinical practice, but potential candidate cytokines have been identified. The aim of the present study was to examine the relationship between candidate cytokines and analgesic response after XRT.Materials and methods: An exploratory analysis was undertaken on biobank data from patients who had received single fraction (8 Gy) XRT for CIBP. The biobank data were prospectively collected from multiple centres in the UK as part of a larger clinical trial, which had institutional review board approval and all patients provided written informed consent for the use of their data in future research. Phenotypic data, pain assessments as well as plasma samples were collected at baseline (within the 24 h before the XRT) and at follow-up (4 weeks after XRT). Baseline and follow-up samples were analysed and levels of 16 preidentified cytokines were compared in patients classified as XRT 'responders' or 'non-responders'.Results: Data from 60 patients were analysed. Insulin-like growth factor binding protein 9 (NOV/CCN3/IGFBP-9) and interleukin-1 beta (IL-1 beta) were identified as potential predictors of response to XRT. A significant relationship was shown between the response to XRT and the ratio of the median level of NOV/CCN3/IGFBP-9 at baseline:follow-up (P = 0.024). Furthermore, for the patients up to 64 years of age, the median level of NOV/CCN3/IGFBP-9 was significantly different between responders and non-responders (P = 0.047). For IL-1 beta, the median level was significantly different between responders and non-responders in patients with breast cancer (P = 0.006).Conclusion: Although the present findings do not identify robust biomarkers, this is the first such study to examine the role of cytokines in predicting response to XRT in patients with CIBP, and studies that build on these findings are encouraged. (C) 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.